IMF Deputy Dan Katz Visits China as Key Economic Review Nears 
Amazon Italy Pays €180M in Compensation as Delivery Staff Probe Ends 
IKEA Launches First New Zealand Store, Marking Expansion Into Its 64th Global Market 
Asian Markets Mixed as Fed Rate Cut Bets Grow and Japan’s Nikkei Leads Gains 
Tesla Expands Affordable Model 3 Lineup in Europe to Boost EV Demand 
China Urged to Prioritize Economy Over Territorial Ambitions, Says Taiwan’s President Lai 
RBI Cuts Repo Rate to 5.25% as Inflation Cools and Growth Outlook Strengthens 
Trump Administration to Secure Equity Stake in Pat Gelsinger’s XLight Startup 
Citi Sets Bullish 2026 Target for STOXX 600 as Fiscal Support and Monetary Easing Boost Outlook 
Airbus Faces Pressure After November Deliveries Dip Amid Industrial Setback 
YouTube Agrees to Follow Australia’s New Under-16 Social Media Ban 
Dollar Holds Steady as Markets Shift Focus to 2026 Rate Cut Expectations 
Europe Confronts Rising Competitive Pressure as China Accelerates Export-Led Growth 
Firelight Launches as First XRP Staking Platform on Flare, Introduces DeFi Cover Feature 
Asian Currencies Edge Higher as Markets Look to Fed Rate Cut; Rupee Steadies Near Record Lows 
Asian Markets Stabilize as Wall Street Rebounds and Rate Concerns Ease 
ExxonMobil to Shut Older Singapore Steam Cracker Amid Global Petrochemical Downturn 
Celltrion, a South Korean pharmaceutical company, formulated a COVID-19 antibody treatment, and it is reportedly ready to deliver the drug to the United States and Europe. With its new treatment, the company has now made the world’s third drug for coronavirus.
Now it is likely to enter the European and U.S. markets before this year ends, as per The Korea Herald. This information was revealed in a report that was released on Monday, Aug. 23.
Lee Dong Geon, an analyst at Shinhan Investment, said that Celltrion will be applying for the issuance of emergency use authorization for its Regkirona COVID-19 antibody treatment. It is hoped that the US Food and Drug Administration will approve this drug that is also called the CT-P59 for EUA.
Moreover, it was predicted that it would not be long until Celltrion’s Regkirona is approved. In fact, it may be out in the U.S. market as early as the fourth quarter of this year. As for the EU market, it was estimated that it could obtain regulatory approval from the Europen Medicine Agency before October since it is already under review.
Apparently, once Celltrion succeeded in rolling out Regkirona in the U.S. and Europe, the company’s position in the pharmaceutical business will surely improve, and this will be felt and observed in the coming months.
In any case, Rekirona is an antibody treatment for coronavirus, and it is the first drug to be developed by Celltrion. It already received a green light from South Korea, Indonesia, and recently, in Brazil. The pharma firm said that as soon as the EMA gives its approval, it will immediately ship the drug to the EU.
Celltrion said that this treatment could shorten the number of treatment days for patients with COVID-19. What’s more, it could also prevent the condition of patients from getting severe.
Meanwhile, as soon as the news of Celltrion’s possible shipment of Regkirona to major markets in the world, Pulse News reported that the company’s shares soared, gaining 6.77 percent to close at ₩284,000 or around $241.97 on Kospi. It was added that it finished 8.21 percent higher and Celltrion Healthcare also went up by 7.94 percent.
